表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗
中的应用
申燕华;钱叶长
【期刊名称】《医药前沿》 【年(卷),期】2013(000)003
【摘要】 肺癌是当今世界上严重威胁人类健康与生命的恶性肿瘤,NSCLC占肺癌总数的80-85﹪.EGFR-TKI在EGFR突变的NSCLC患者的治疗中取得了良好的效果,但NSCLC对EGFR-TKI产生耐药性也逐渐受到重视.本文主要对EGFR基因突变的检测、EGFR-TKI对NSCLC的治疗以及NSCLC对EGFR-TKI耐药的机制及对策进行综述.%Lung cancer is a highly malignant tumor which is the most threatening disease of the human health and life, and 80-85﹪ of the disease is non-smal cel lung cancer (NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has obtained the good effect in the treatment of NSCLC patients with EGFR mutation. But it is also getting increasing attention about NSCLC drug resistance to EGFR-TKI. This paper summarized the detection of the EGFR gene mutation, the effect of EGRF-TKI on the treatment of NSCLC patients, and the pathogenesis and countermeasures about NSCLC drug resistance to EGFR-TKI. 【总页数】2页(333-334)
【关键词】表皮生长因子受体;酪氨酸激酶抑制剂;癌;非小细胞肺 【作者】申燕华;钱叶长
表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌治疗中的应用
